This study investigates the safety of combining several chemotherapy drugs for the treatment of certain gastrointestinal cancers, including pancreatic adenocarcinoma and gastroesophageal adenocarcinoma. The study involves using irinotecan, 5-FU, leucovorin/folinic acid, oxaliplatin, and docetaxel together.
The purpose of this study is to evaluate how these combined chemotherapies work together in terms of safety for patients. The study will look at different aspects to ensure that the combination does not cause unexpected side effects.
- Who can participate: Adults aged 18 and older with specific gastrointestinal cancers can participate. Key eligibility includes adequate organ function and a life expectancy of more than 3 months.
- Study details: Participants will receive a combination of investigational medicines. They will not receive a placebo.
How understandable was the trial content above?
Hard to understand
Easy to understand